ClinicalTrials.gg
TerminatedNCT05403476Updated Aug 28, 2026Results posted

A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)

A Phase 2 interventional study of FE 999049 and Placebo in Male Idiopathic Infertility, sponsored by Ferring Pharmaceuticals. Terminated at 22 sites in 7 countries. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Ferring Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
The probability of enrolling subjects in the trial in a reasonable timeframe was too low. The termination was not due to safety concerns nor changes in Ferring's Reproductive Medicine strategy or interest in developing treatments for Male Infertility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.

Enrollment
13th of 13
4 · median 220
Started
2022
with 1 other
Phase 2
5 of 13
1 open now
Registered
12th of 13
by date
Lead sponsor
10 of 13
Ferring Pharmaceuticals

Among the 13 studies testing follitropin delta in Infertility, this one is the 13th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 12th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About follitropin delta

follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 50 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing follitropin delta in Infertility, or all of them as a file.
02

Study summary

The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed in their female partners in comparison to placebo (inactive treatment). For more information, please visit the trial's website www.adamclinicaltrial.com (only applicable in the US).

03

Conditions studied

  • Male Idiopathic Infertility

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of infertility with current partner at randomisation must be 12-60 months if current partner is aged \<35 years or 6-60 months if current partner is aged 35-38 years.
  • Men between the ages of 18 and 50 years.
  • Total sperm count 5-39 million at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomization.
  • Total sperm motility of ≥10% at screening; confirmed by two samples taken ≥2 weeks apart before randomisation. If a semen sample has been taken within 3 months prior to screening and been analysed at an andrology laboratory, it can be included as the first of the two semen samples at screening.
  • Semen volume ≥1.4 mL at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomization.
  • Serum follicle-stimulating hormone (FSH) levels of 2-12.0 IU/L (measured at central laboratory) at screening)
  • Serum luteinising hormone (LH) levels of 1.2-7.5 IU/L (measured at central laboratory) at screening.
  • Serum total testosterone levels of ≥300 ng/dL (equals ≥10.4 nmol/L; measured at central laboratory) at screening.
  • Agree to have regular intercourse with current female partner with the intent of spontaneous conception within 9 months from randomization.
  • Agree to provide information on female partner's positive urine pregnancy test(s) and documentation of ultrasound(s), delivery, and neonatal/infant health.

Current partner fulfilling the criteria below:

  • Pre-menopausal woman between the ages of 18 and 38 years (both inclusive) at the time of randomisation of male participant.
  • Regular menstrual cycles of 21-35 days.
  • No history or current condition of pelvic inflammatory disease, endometriosis stage II-IV by definite or empirical diagnosis, or tubal ligation.
  • Agree not to obtain infertility treatment outside of this trial for 6 months from randomization of male subject.

Exclusion criteria

Exclusion Criteria:

  • Previous FSH treatment for ≥4 months not leading to conception.
  • Past or current use of finasteride within 3 months prior to screening.
  • Any history of anatomical disorder of the pituitary gland or testes.
  • Any structural abnormalities of the vas deferens (unilateral or bilateral) at screening.
  • Any known, , systemic disease in addition to the trial indication that might negatively impact fertility.
  • Known history or presence of clinical varicocele (subclinical and Grade 1 varicocele are acceptable).
  • Known history of cryptorchidism, testicular torsion, or orchitis.
  • Known abnormal karyotype (including Y-chromosome microdeletion).
  • Current or past treatment of urogenital (kidney, bladder, testicular, or prostate) cancer as well as history of chemo- or radiotherapy that can have impact on testes.
  • Any known uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders).
  • Administration of hormonal preparations, agents known to impair testicular function or affect sex hormone secretion, and known or suspected teratogens within 3 months prior to screening. Administration of anabolic steroids within 12 months prior to screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    FE 999049 (Follitropin Delta)

    Drug: FE 999049

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.

    Also known as: REKOVELLE, Follitropin Delta

  • DrugPlacebo

    Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.

06

What researchers measure

Primary outcomes

  1. Spontaneous Pregnancy Observed in Female Partner Within 9 Months After Randomization of Male Subject, Where Spontaneous Pregnancy is Defined as Vital Pregnancy

    Vital pregnancy is documentation of at least one intrauterine gestational sac with fetal heartbeat by ultrasound.

    Time frame: Up to 9 months after randomization

Secondary outcomes

  1. Positive Beta-Human Chorionic Gonadotropins (βhCG) (Positive Urine βhCG Test) Observed in Female Partner

    Time frame: Up to 9 months (End-of-Trial)

  2. Time From Randomization to Spontaneous Pregnancy Observed in Female Partner.

    Time frame: 9 months

  3. Changes in Semen Volume From Pre-randomisation to 9 Months After Randomization

    Change from baseline pre-randomisation to end of trial, which is 9 months.

    Time frame: From pre-randomisation to end of trial (9 months)

  4. Changes in Sperm Concentration

    Change from baseline from pre-randomisation to end of trial, which is 9 months

    Time frame: From pre-randomization to end of trial (9 months)

  5. Changes in Total Sperm Count

    Change from baseline from pre-randomisation to end of trial, which is 9 months

    Time frame: From pre-randomisation to end of trial (9 months)

  6. Changes in Total Motile Sperm Count

    Change from baseline from pre-randomisation to end of trial, which is 9 months

    Time frame: From pre-randomisation to end of trial (9 months)

  7. Changes in Sperm Morphology

    Change from baseline from pre-randomisation to end of trial, which is 9 months

    Time frame: From pre-randomisation to end of trial (up to 9 months)

  8. Changes in Semen DNA Fragmentation

    Time frame: From pre-randomization to end of treatment

  9. Treatment Responders Defined by Either Spontaneous Pregnancy Observed in Female Partner, or Increase of Total Sperm Count or Total Motile Sperm Count to 50% Over Average Baseline at 6 and/or 9 Months

    Time frame: Baseline to 6 and 9 months

  10. Changes in Follicle Stimulating Hormone (FSH)

    Change from baseline.

    Time frame: From randomization to 6 months after randomization

  11. Changes in Luteinising Hormone (LH)

    From randomisation to 3 and 6 months

    Time frame: From randomisation to 3 and 6 months after randomization

  12. Changes in Inhibin B

    Change from baseline.

    Time frame: From randomization to 6 months after randomization

  13. Changes in Testosterone

    Change from baseline.

    Time frame: From randomization to 6 months after randomization

  14. Changes in Estradiol

    Change from baseline.

    Time frame: From randomization to 6 months after randomization

  15. Changes in Free Testosterone Concentration

    Blood samples for assessment of sex hormone binding globulin (SHBG) concentrations will be drawn in order to calculate change from baseline in free testosterone concentrations.

    Time frame: From randomization to 6 months after randomization

  16. Number of Participants With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity

    Blood samples for assessment of anti-FSH antibodies will be drawn.

    Time frame: From randomization to 21-35 days after End-of-treatment (9 months)

  17. Number of Participants With Immune-related Adverse Events

    All treatment-emergent adverse events will be analyzed to identify those that potentially are immune related.

    Time frame: From randomization to End-of-Trial (up to 9 months)

07

Results

Posted Aug 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneFE 999049 (Follitropin Delta)Placebo
Started13
Completed13
Not completed00

Outcome measures

PrimarySpontaneous Pregnancy Observed in Female Partner Within 9 Months After Randomization of Male Subject, Where Spontaneous Pregnancy is Defined as Vital Pregnancy

Vital pregnancy is documentation of at least one intrauterine gestational sac with fetal heartbeat by ultrasound.

Time frame:
Up to 9 months after randomization
Reported as:
Count of participants · Participants
Spontaneous Pregnancy Observed in Female Partner Within 9 Months After Randomization of Male Subject, Where Spontaneous Pregnancy is Defined as Vital Pregnancy
ParticipantsFE 999049 (Follitropin Delta)Placebo
Spontaneous Pregnancy Observed in Female Partner Within 9 Months After Randomization of Male Subject, Where Spontaneous Pregnancy is Defined as Vital Pregnancy00
SecondaryPositive Beta-Human Chorionic Gonadotropins (βhCG) (Positive Urine βhCG Test) Observed in Female Partner
Time frame:
Up to 9 months (End-of-Trial)
Reported as:
Count of participants · Participants
Positive Beta-Human Chorionic Gonadotropins (βhCG) (Positive Urine βhCG Test) Observed in Female Partner
ParticipantsFE 999049 (Follitropin Delta)Placebo
Positive Beta-Human Chorionic Gonadotropins (βhCG) (Positive Urine βhCG Test) Observed in Female Partner00
SecondaryTime From Randomization to Spontaneous Pregnancy Observed in Female Partner.
Time frame:
9 months
Reported as:
Number · Days
Time From Randomization to Spontaneous Pregnancy Observed in Female Partner.
DaysFE 999049 (Follitropin Delta)Placebo
Time From Randomization to Spontaneous Pregnancy Observed in Female Partner.—NA
SecondaryChanges in Semen Volume From Pre-randomisation to 9 Months After Randomization

Change from baseline pre-randomisation to end of trial, which is 9 months.

Time frame:
From pre-randomisation to end of trial (9 months)
Reported as:
Median · mL
Changes in Semen Volume From Pre-randomisation to 9 Months After Randomization
mLFE 999049 (Follitropin Delta)Placebo
Changes in Semen Volume From Pre-randomisation to 9 Months After Randomization0.5 (0.5 to 0.5)-1.25 (-2.5 to 0.95)
SecondaryChanges in Sperm Concentration

Change from baseline from pre-randomisation to end of trial, which is 9 months

Time frame:
From pre-randomization to end of trial (9 months)
Reported as:
Median · x10^6 sperm/mL
Changes in Sperm Concentration
x10^6 sperm/mLFE 999049 (Follitropin Delta)Placebo
Changes in Sperm Concentration-2.14 (-2.14 to -2.14)-0.7 (-1.2 to 2.0)
SecondaryChanges in Total Sperm Count

Change from baseline from pre-randomisation to end of trial, which is 9 months

Time frame:
From pre-randomisation to end of trial (9 months)
Reported as:
Median · x10^6 sperm
Changes in Total Sperm Count
x10^6 spermFE 999049 (Follitropin Delta)Placebo
Changes in Total Sperm Count-13.01 (-13.01 to -13.01)-3.75 (-15.9 to -0.75)
SecondaryChanges in Total Motile Sperm Count

Change from baseline from pre-randomisation to end of trial, which is 9 months

Time frame:
From pre-randomisation to end of trial (9 months)
Reported as:
Median · x10^6 sperm
Changes in Total Motile Sperm Count
x10^6 spermFE 999049 (Follitropin Delta)Placebo
Changes in Total Motile Sperm Count-3.74 (-3.74 to -3.74)-0.965 (-3.71 to 0.24)
SecondaryChanges in Sperm Morphology

Change from baseline from pre-randomisation to end of trial, which is 9 months

Time frame:
From pre-randomisation to end of trial (up to 9 months)
Reported as:
Median · % of sperm with normal shape
Changes in Sperm Morphology
% of sperm with normal shapeFE 999049 (Follitropin Delta)Placebo
Changes in Sperm Morphology—0.0 (-2.0 to 5.0)
SecondaryChanges in Semen DNA Fragmentation
Time frame:
From pre-randomization to end of treatment

No measurements were reported for this outcome.

SecondaryTreatment Responders Defined by Either Spontaneous Pregnancy Observed in Female Partner, or Increase of Total Sperm Count or Total Motile Sperm Count to 50% Over Average Baseline at 6 and/or 9 Months
Time frame:
Baseline to 6 and 9 months
Reported as:
Count of participants · Participants
Treatment Responders Defined by Either Spontaneous Pregnancy Observed in Female Partner, or Increase of Total Sperm Count or Total Motile Sperm Count to 50% Over Average Baseline at 6 and/or 9 Months
ParticipantsFE 999049 (Follitropin Delta)Placebo
Treatment Responders Defined by Either Spontaneous Pregnancy Observed in Female Partner, or Increase of Total Sperm Count or Total Motile Sperm Count to 50% Over Average Baseline at 6 and/or 9 Months02
SecondaryChanges in Follicle Stimulating Hormone (FSH)

Change from baseline.

Time frame:
From randomization to 6 months after randomization
Reported as:
Median · IU/L
Changes in Follicle Stimulating Hormone (FSH)
IU/LFE 999049 (Follitropin Delta)Placebo
Changes in Follicle Stimulating Hormone (FSH)2.10 (2.10 to 2.10)0.10 (-0.50 to 2.30)
SecondaryChanges in Luteinising Hormone (LH)

From randomisation to 3 and 6 months

Time frame:
From randomisation to 3 and 6 months after randomization
Reported as:
Median · IU/L
Changes in Luteinising Hormone (LH)
IU/LFE 999049 (Follitropin Delta)Placebo
3 months-0.76 (-0.76 to -0.76)-0.46 (-0.61 to -0.22)
6 months1.23 (1.23 to 1.23)0.28 (-0.37 to 1.85)
SecondaryChanges in Inhibin B

Change from baseline.

Time frame:
From randomization to 6 months after randomization
Reported as:
Median · pg/mL
Changes in Inhibin B
pg/mLFE 999049 (Follitropin Delta)Placebo
Changes in Inhibin B28.0 (28.0 to 28.0)-4.0 (-19.0 to 16)
SecondaryChanges in Testosterone

Change from baseline.

Time frame:
From randomization to 6 months after randomization
Reported as:
Median · nmol/L
Changes in Testosterone
nmol/LFE 999049 (Follitropin Delta)Placebo
Changes in Testosterone6.25 (6.25 to 6.25)-0.35 (-2.43 to 4.85)
SecondaryChanges in Estradiol

Change from baseline.

Time frame:
From randomization to 6 months after randomization
Reported as:
Median · pmol/L
Changes in Estradiol
pmol/LFE 999049 (Follitropin Delta)Placebo
Changes in Estradiol47.5 (47.5 to 47.5)33.0 (0.0 to 69.0)
SecondaryChanges in Free Testosterone Concentration

Blood samples for assessment of sex hormone binding globulin (SHBG) concentrations will be drawn in order to calculate change from baseline in free testosterone concentrations.

Time frame:
From randomization to 6 months after randomization
Reported as:
Median · nmol/L
Changes in Free Testosterone Concentration
nmol/LFE 999049 (Follitropin Delta)Placebo
Changes in Free Testosterone Concentration6.25 (6.25 to 6.25)-0.35 (-2.43 to 4.85)
SecondaryNumber of Participants With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity

Blood samples for assessment of anti-FSH antibodies will be drawn.

Time frame:
From randomization to 21-35 days after End-of-treatment (9 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity
ParticipantsFE 999049 (Follitropin Delta)Placebo
Number of Participants With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity00
SecondaryNumber of Participants With Immune-related Adverse Events

All treatment-emergent adverse events will be analyzed to identify those that potentially are immune related.

Time frame:
From randomization to End-of-Trial (up to 9 months)
Reported as:
Count of participants · Participants
Number of Participants With Immune-related Adverse Events
ParticipantsFE 999049 (Follitropin Delta)Placebo
Number of Participants With Immune-related Adverse Events00

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FE 999049 (Follitropin Delta)0/1 (0%)0/1 (0%)0/1 (0%)
Placebo0/3 (0%)0/3 (0%)0/3 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)FE 999049 (Follitropin Delta)PlaceboTotal
18 - 50 years134
Sex: Female, Male
Sex: Female, Male(Participants)FE 999049 (Follitropin Delta)PlaceboTotal
Female000
Male134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FE 999049 (Follitropin Delta)PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White134
More than one race000
Unknown or Not Reported000
08

Study locations

22 sites
  • Ferring Investigational Site
    Tempe, Arizona 85284, United States
  • Ferring Investigational Site
    San Jose, California 95124, United States
  • Ferring Investigational Site
    Centennial, Colorado 80112, United States
  • Ferring Investigational Site
    Newark, Delaware 19713, United States
  • Ferring Investigational Site
    Chicago, Illinois 60612, United States
  • Ferring Investigational Site
    Kansas City, Kansas 66160, United States
  • Ferring Investigational Site
    New York, New York 10065, United States
  • Ferring Investigational Site
    Raleigh, North Carolina 27607, United States
  • Ferring Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Ferring Investigational Site
    Bedford, Texas 76022, United States
  • Ferring investigational site
    Webster, Texas 77598, United States
  • Ferring Investigational Site
    Salt Lake City, Utah 84108, United States
  • Ferring Investigational Site
    Seattle, Washington 98195, United States
  • Ferring Investigational Site
    Brussels, Belgium
  • Ferring Investigational Site
    Copenhagen, Denmark
  • Ferring Investigational Site
    Halle, Germany
  • Ferring Investigational Site
    Münster, Germany
  • Ferring Investigational Site
    Modena, Italy
  • Ferring Investigational Site
    Rome, Italy
  • Ferring Investigational Site
    Valencia, Spain
  • Ferring Investigational Site
    Malmö, Sweden
  • Ferring Investigational Site
    Stockholm, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Oct 2024, 25 months.

Results were first posted in Aug 2026, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Jun 3, 2022
StartActual
Aug 16, 2022
Primary completionActual
Oct 5, 2024
CompletionActual
Oct 23, 2024
Results first posted
Aug 28, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05403476
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
Aug 16, 2022
Primary completion
Oct 5, 2024
Completion
Oct 23, 2024
Results posted
Aug 28, 2026
Last update
Aug 28, 2026

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion